Literature DB >> 9330549

Evidence for reliability, validity and usefulness of the Medical Outcomes Study HIV Health Survey (MOS-HIV).

A W Wu1, D A Revicki, D Jacobson, F E Malitz.   

Abstract

The Medical Outcomes Study HIV Health Survey (MOS-HIV) is a brief, comprehensive measure of health-related quality of life (HRQoL) used extensively in human immunodeficiency virus/acquired immune deficiency syndrome (HIV/AIDS). The 35-item questionnaire includes ten dimensions (health perceptions, pain, physical, role, social and cognitive functioning, mental health, energy, health distress and quality of life (QoL) and takes approximately 5 minutes to complete. Subscales are scored on a 0-100 scale (a higher score indicates better health) and physical and mental health summary scores can be generated. The MOS-HIV has been shown to be internally consistent, correlate with concurrent measures of health, discriminate between distinct groups, predict future outcomes and be responsive to changes over time. Limited experience suggests acceptable reliability and validity in women, injecting drug users and African-American and lower socioeconomic status patients. The MOS-HIV is available in 14 languages and has been included as a secondary outcome measure in numerous clinical trials for all stages of disease. In several studies it has detected significant differences between treatments; in some cases concordant with conventional endpoints and, in others, discordant. The interpretation of scores is facilitated by an explanation in terms meaningful to the intended audience. Research is needed to compare the MOS-HIV to other strategies for HRQoL assessment in early HIV disease.

Entities:  

Mesh:

Year:  1997        PMID: 9330549     DOI: 10.1023/a:1018451930750

Source DB:  PubMed          Journal:  Qual Life Res        ISSN: 0962-9343            Impact factor:   4.147


  31 in total

1.  The MOS short-form general health survey. Reliability and validity in a patient population.

Authors:  A L Stewart; R D Hays; J E Ware
Journal:  Med Care       Date:  1988-07       Impact factor: 2.983

2.  The reliability and validity of two HIV-specific health-related Quality-of-Life measures: a preliminary analysis.

Authors:  A Burgess; M Dayer; J Catalan; D Hawkins; B Gazzard
Journal:  AIDS       Date:  1993-07       Impact factor: 4.177

Review 3.  Methods for quality-of-life studies.

Authors:  M A Testa; J F Nackley
Journal:  Annu Rev Public Health       Date:  1994       Impact factor: 21.981

4.  Measuring visual function and quality of life in patients with cytomegalovirus retinitis. Development of a questionnaire. Studies of Ocular Complication of AIDS Research Group.

Authors:  A W Wu; L C Coleson; J Holbrook; D A Jabs
Journal:  Arch Ophthalmol       Date:  1996-07

5.  Quality of life assessment in pregnant women with the human immunodeficiency virus.

Authors:  K D Larrabee; M Monga; N Eriksen; A Helfgott
Journal:  Obstet Gynecol       Date:  1996-12       Impact factor: 7.661

6.  Functional status and well-being in a placebo-controlled trial of zidovudine in early symptomatic HIV infection.

Authors:  A W Wu; H R Rubin; W C Mathews; L M Brysk; S A Bozzette; W D Hardy; J H Atkinson; I Grant; S A Spector; J A McCutchan
Journal:  J Acquir Immune Defic Syndr (1988)       Date:  1993-05

7.  Clarithromycin therapy for bacteremic Mycobacterium avium complex disease. A randomized, double-blind, dose-ranging study in patients with AIDS. AIDS Clinical Trials Group Protocol 157 Study Team.

Authors:  R E Chaisson; C A Benson; M P Dube; L B Heifets; J A Korvick; S Elkin; T Smith; J C Craft; F R Sattler
Journal:  Ann Intern Med       Date:  1994-12-15       Impact factor: 25.391

8.  Combination foscarnet and ganciclovir therapy vs monotherapy for the treatment of relapsed cytomegalovirus retinitis in patients with AIDS. The Cytomegalovirus Retreatment Trial. The Studies of Ocular Complications of AIDS Research Group in Collaboration with the AIDS Clinical Trials Group.

Authors: 
Journal:  Arch Ophthalmol       Date:  1996-01

9.  The safety and efficacy of zidovudine (AZT) in the treatment of subjects with mildly symptomatic human immunodeficiency virus type 1 (HIV) infection. A double-blind, placebo-controlled trial. The AIDS Clinical Trials Group.

Authors:  M A Fischl; D D Richman; N Hansen; A C Collier; J T Carey; M F Para; W D Hardy; R Dolin; W G Powderly; J D Allan
Journal:  Ann Intern Med       Date:  1990-05-15       Impact factor: 25.391

10.  Zidovudine in asymptomatic human immunodeficiency virus infection. A controlled trial in persons with fewer than 500 CD4-positive cells per cubic millimeter. The AIDS Clinical Trials Group of the National Institute of Allergy and Infectious Diseases.

Authors:  P A Volberding; S W Lagakos; M A Koch; C Pettinelli; M W Myers; D K Booth; H H Balfour; R C Reichman; J A Bartlett; M S Hirsch
Journal:  N Engl J Med       Date:  1990-04-05       Impact factor: 91.245

View more
  201 in total

1.  Continued high prevalence and adverse clinical impact of human immunodeficiency virus-associated sensory neuropathy in the era of combination antiretroviral therapy: the CHARTER Study.

Authors:  Ronald J Ellis; Debralee Rosario; David B Clifford; Justin C McArthur; David Simpson; Terry Alexander; Benjamin B Gelman; Florin Vaida; Ann Collier; Christina M Marra; Beau Ances; J Hampton Atkinson; Robert H Dworkin; Susan Morgello; Igor Grant
Journal:  Arch Neurol       Date:  2010-05

2.  Psychometric evaluation of the HIV symptom distress scale.

Authors:  Linda G Marc; Ming-Mei Wang; Marcia A Testa
Journal:  AIDS Care       Date:  2012-03-12

3.  Clinical significance of hyperbilirubinemia among HIV-1-infected patients treated with atazanavir/ritonavir through 96 weeks in the CASTLE study.

Authors:  Cheryl McDonald; Jonathan Uy; Wenhua Hu; Victoria Wirtz; Salome Juethner; David Butcher; Donnie McGrath; Awny Farajallah; Graeme Moyle
Journal:  AIDS Patient Care STDS       Date:  2012-03-09       Impact factor: 5.078

4.  [Economic aspects of ambulatory and inpatient treatment of HIV positive patients].

Authors:  M Stoll; R E Schmidt
Journal:  Internist (Berl)       Date:  2003-06       Impact factor: 0.743

5.  Validation of the medical outcomes study HIV (MOS-HIV) health survey among HIV-infected patients in Taiwan.

Authors:  Ping-Chuan Hsiung; Chi-Tai Fang; Keng-Lin Lee; Wang-Huei Sheng; Chia-Yun Wu; Jung-Der Wang; Grace Yao
Journal:  Qual Life Res       Date:  2010-08-29       Impact factor: 4.147

6.  Two-way text messaging for health behavior change among human immunodeficiency virus-positive individuals.

Authors:  Lynne T Harris; Keren Lehavot; David Huh; Samantha Yard; Michele P Andrasik; Peter J Dunbar; Jane M Simoni
Journal:  Telemed J E Health       Date:  2010-11-18       Impact factor: 3.536

7.  Assessment of quality of life among HIV-infected persons in Pune, India.

Authors:  Rewa M Kohli; Suvarna Sane; Kishore Kumar; Ramesh S Paranjape; Sanjay M Mehendale
Journal:  Qual Life Res       Date:  2005-08       Impact factor: 4.147

8.  Epoetin alfa increases hemoglobin levels and improves quality of life in anemic geriatric cancer patients receiving chemotherapy.

Authors:  Matti S Aapro; David C Dale; Michael Blasi; Brenda Sarokhan; Fawzia Ahmed; Richard C Woodman
Journal:  Support Care Cancer       Date:  2006-06-07       Impact factor: 3.603

9.  Quality of life among people treated for tuberculosis and human immunodeficiency virus in Rio de Janeiro, Brazil.

Authors:  D W Dowdy; G Israel; V Vellozo; V Saraceni; S Cohn; S Cavalcante; R E Chaisson; J E Golub; B Durovni
Journal:  Int J Tuberc Lung Dis       Date:  2013-01-14       Impact factor: 2.373

10.  The combined effect of relaxation response and acupuncture on quality of life in patients with HIV: a pilot study.

Authors:  Bei-Hung Chang; Ulrike Boehmer; Yue Zhao; Elizabeth Sommers
Journal:  J Altern Complement Med       Date:  2007-10       Impact factor: 2.579

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.